Kenneth Kolinsky
Overview
Explore the profile of Kenneth Kolinsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al.
Cancer Res
. 2010 Jun;
70(13):5518-27.
PMID: 20551065
The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical...
12.
Traina T, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis C, et al.
Breast Dis
. 2010 Jun;
31(1):7-18.
PMID: 20519801
Background: to hasten and improve anticancer drug development, we created a novel approach to generating and analyzing preclinical dose-scheduling data so as to optimize benefit-to-toxicity ratios. Methods: we applied mathematical...
13.
Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, et al.
Mol Cancer Ther
. 2010 Jan;
9(1):134-44.
PMID: 20053779
Targeting the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway represents a promising anticancer strategy. Recently, we have reported a novel class of potent and selective non-ATP-competitive MEK1/2 inhibitors...
14.
Kolinsky K, Zhang Y, Dugan U, Heimbrook D, Packman K, Higgins B
Anticancer Res
. 2009 Apr;
29(1):91-8.
PMID: 19331137
Background: Xenograft and mathematical models have shown that the antitumor activity of capecitabine can be increased by modifying the schedule from 14 days on, 7 off (14/7) to 7/7. Materials...
15.
Daouti S, Wang H, Li W, Higgins B, Kolinsky K, Packman K, et al.
Cancer Res
. 2009 Feb;
69(5):1924-32.
PMID: 19244124
The mitogen-activated protein kinase (MAPK) signal transduction pathway plays a central role in regulating tumor cell growth, survival, differentiation, and angiogenesis. The key components of the Ras/Raf/MEK/ERK signal module are...
16.
Kolinsky K, Shen B, Zhang Y, Kohles J, Dugan U, Zioncheck T, et al.
Mol Cancer Ther
. 2009 Jan;
8(1):75-82.
PMID: 19139115
Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in...
17.
Higgins B, Kolinsky K, Linn M, Adames V, Zhang Y, Moisa C, et al.
Anticancer Res
. 2007 Aug;
27(4B):2279-87.
PMID: 17695515
Background: Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it...
18.
DePinto W, Chu X, Yin X, Smith M, Packman K, Goelzer P, et al.
Mol Cancer Ther
. 2006 Nov;
5(11):2644-58.
PMID: 17121911
The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of distinct cyclin-dependent kinase (CDK) complexes results in escape of cells from cell cycle...
19.
Chen J, Smith M, Kolinsky K, Adames V, Mehta N, Fritzky L, et al.
Cancer Chemother Pharmacol
. 2006 Aug;
59(5):651-9.
PMID: 16937104
Erlotinib (Tarceva, OSI-774) is a potent, orally available, small-molecule inhibitor of HER1/EGFR tyrosine-kinase activity. In this study, the antitumor activity of erlotinib was evaluated in two human colorectal tumor xenograft...
20.
Muruganandham M, Lupu M, Dyke J, Matei C, Linn M, Packman K, et al.
Mol Cancer Ther
. 2006 Aug;
5(8):1950-7.
PMID: 16928815
Inhibition of tumor angiogenesis is a promising approach in cancer treatment. The purpose of this study was to evaluate the vascular response of human lung tumor xenografts in vivo to...